Superficial bladder cancer

被引:13
|
作者
Lamm D.L. [1 ]
机构
[1] Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, 85259, AZ
关键词
Bladder Cancer; Contraindication Hypersensitivity; Main Drug Interaction; Superficial Bladder Cancer; Thiotepa;
D O I
10.1007/s11864-002-0005-4
中图分类号
学科分类号
摘要
Superficial bladder cancer can be resected with minimal morbidity, but the patients are at high risk for tumor recurrence. Tumors can be divided into low-, intermediate-, and high-risk categories based on tumor grade, stage, and pattern of recurrence. Low-risk tumors are best treated with a single instillation of chemotherapy such as thiotepa, doxorubicin, or mitomycin. Intermediate-risk tumors can be treated with chemotherapy, but, similar to high-risk tumors, will often require immunotherapy. High-risk tumors are best treated with intravesical bacille Calmette-Guerin (BCG) using a 3-week maintenance schedule. Side effects of BCG immunotherapy can be reduced by logarithmic reductions in the dosage of BCG. Patients who fail BCG may be rescued with BCG plus interferon-alfa or radical cystectomy. © 2002, Current Science Inc.
引用
收藏
页码:403 / 411
页数:8
相关论文
共 50 条
  • [1] The management of superficial bladder cancer
    Dalbagni, Guido
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (05): : 254 - 260
  • [2] SUPERFICIAL BLADDER-CANCER
    TRYBULA, M
    KING, M
    MEDICAL AND PEDIATRIC ONCOLOGY, 1985, 13 (06): : 384 - 389
  • [3] SUPERFICIAL BLADDER-CANCER
    ITOKU, KA
    STEIN, BS
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (01) : 99 - 116
  • [4] SUPERFICIAL BLADDER-CANCER
    ABEL, PD
    BRITISH MEDICAL JOURNAL, 1993, 306 (6890): : 1480 - 1480
  • [5] Immunotherapy for superficial bladder cancer
    Schenk-Braat, EAM
    Bangma, CH
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) : 414 - 423
  • [6] Editorial: Superficial bladder cancer
    Kirkali, Ziya
    THESCIENTIFICWORLDJOURNAL, 2006, 6 : 2646 - 2646
  • [7] Immunotherapy for superficial bladder cancer
    Ellen A. M. Schenk-Braat
    Chris H. Bangma
    Cancer Immunology, Immunotherapy, 2005, 54 : 414 - 423
  • [8] BCG in superficial bladder cancer
    不详
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (09) : 1158 - 1158
  • [9] The management of superficial bladder cancer
    Guido Dalbagni
    Nature Clinical Practice Urology, 2007, 4 : 254 - 260
  • [10] Chemoprevention of superficial bladder cancer
    Gee, J
    Sabicihi, AL
    Grossman, HB
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 43 (03) : 277 - 286